Survival rates

Survival rates show how many people in a group are alive after a set number of years. For example, a five-year survival rate is the percentage of people alive five years after diagnosis. Survival statistics describe groups. They cannot tell exactly how long one person will live.

Survival statistics

The estimated five-year overall survival rates based on the MSS-WM for a test group were:

  • Low risk: about 93%.
  • Low-intermediate risk: about 90%.
  • Intermediate risk: about 75%.
  • High risk: about 57%.

The estimated 10-year overall survival rates in the same group were:

  • Low risk: about 91%.
  • Low-intermediate risk: about 80%.
  • Intermediate risk: about 64%.
  • High risk: about 35%.

Severe Waldenstrom macroglobulinemia or its complications can be life-threatening. The exact cause of death varies from person to person. In people older than 65, the most common cause of death is not cancer related.

Outlook

For active or symptomatic Waldenstrom macroglobulinemia, the Modified Staging System for Waldenstrom Macroglobulinemia (MSS-WM) uses age and two blood tests, albumin and lactate dehydrogenase (LDH), to estimate risk group and outlook. People in lower risk groups usually live longer than people in higher risk groups.

MSS-WM groups help healthcare professionals talk about outlook. A risk group cannot predict exactly how long you will live. Survival with Waldenstrom macroglobulinemia has improved over time, but each person's outlook is different.

Life expectancy with Waldenstrom macroglobulinemia varies widely. One recent review found a median survival of more than 10 years for people diagnosed before age 70. Median survival was about seven years for people ages 70 to 79 and about four years for people age 80 or older. Median survival is the length of time at which half of the people in a group are still living.

These numbers describe groups, not what will happen to one person. Age has a strong effect on survival.

Some people with Waldenstrom macroglobulinemia live for many years after diagnosis. Long-term survival depends on age, how the condition is affecting you, complications and how well the cancer responds to treatment.

Group statistics cannot predict whether one person will live 20 years or longer. Some people do live for many years after diagnosis, but individual outlook varies.

Survival statistics take years to collect. The latest numbers include people who were treated more than five years ago. Some of them did not have access to today's newer treatments. But survival rates are improving.

What you can do

Ask your healthcare team what the survival numbers mean for you. Keep follow-up visits and report new or changing symptoms so your healthcare team can watch your condition and decide when treatment may be needed.

Oct. 17, 2026

Living with waldenstrom macroglobulinemia?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

cindyem
Primary Myelofibrosis with JAK2: Anyone have Ojjaara (momelotinib)?

37 Replies Thu, Oct 15, 2026

clavallee2
Anyone diagnosed with Primary Central Nervous System (CNS) Lymphoma?

105 Replies Thu, Oct 15, 2026

hikerny
Anyone have chronic lymphocytic leukemia (CLL)?

406 Replies Wed, Oct 14, 2026

See more discussions
  1. Pemov A, et al. The landscape of rare genetic variants in familial Waldenström macroglobulinemia. Blood Neoplasia. 2024; doi:10.1016/j.bneo.2024.100013.
  2. Gertz MA. Waldenström macroglobulinemia: 2025 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2025; doi:10.1002/ajh.27666.
  3. Kapoor P, et al. Current approach to Waldenström macroglobulinemia. Blood Reviews. 2023; doi:10.1016/j.blre.2023.101129.
  4. Zanwar S, et al. Diagnosis and risk stratification in Waldenström macroglobulinemia. Journal of the National Comprehensive Cancer Network. 2024; doi:10.6004/jnccn.2024.7024.
  5. Sarosiek S, et al. Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's macroglobulinemia. Seminars in Hematology. 2025; doi:10.1053/j.seminhematol.2025.04.005.
  6. Kumar SK, et al. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2024; doi:10.6004/jnccn.2024.0001.
  7. Waldenstrom macroglobulinemia. American Cancer Society. https://www.cancer.org/cancer/types/waldenstrom-macroglobulinemia.html. Accessed Aug. 26, 2026.
  8. Ferri FF. Waldenström macroglobulinemia. In: Ferri's Clinical Advisor 2027. Elsevier; 2027. https://www.clinicalkey.com. Accessed Aug. 26, 2026.
  9. Zanwar S, et al. Simplified risk stratification model for patients with Waldenström macroglobulinemia. Journal of Clinical Oncology. 2024; doi:10.1200/JCO.23.02066.
  10. McMaster ML. The epidemiology of Waldenström macroglobulinemia. Seminars in Hematology. 2023; doi:10.1053/j.seminhematol.2023.03.008.
  11. Treon SP, et al. Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Seminars in Hematology. 2023; doi:10.1053/j.seminhematol.2023.03.009.
  12. Garcia-Sanz R, et al. Report of Consensus Panel 3 from the 11th International Workshop on Waldenström's macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's macroglobulinemia. Seminars in Hematology. 2023; doi:10.1053/j.seminhematol.2023.03.007.
  13. Buske C, et al. Report of Consensus Panel 1 from the 11th International Workshop on Waldenstrom's macroglobulinemia on management of symptomatic, treatment-naïve patients. Seminars in Hematology. 2023; doi:10.1053/j.seminhematol.2023.03.005.
  14. Medical review (expert opinion). Mayo Clinic. Oct. 5, 2026.